Guggenheim initiated coverage on Sionna Therapeutics with a new price target
$SION
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $45.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2025 | Buy | TD Cowen | |
| 3/4/2025 | $32.00 | Buy | Stifel |
| 3/4/2025 | $45.00 | Buy | Guggenheim |
Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position following completed upsized IPO, with approximately $354.7 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for c
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 12:30 p.m. ET. A live webcast of the presentation will be available the day of the event on the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will be available for 90
Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025, with topline data for both anticipated in mid-2026 Completed upsized IPO with gross proceeds of approximately $219 million, extending runway into 2028 WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, I
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
TD Cowen initiated coverage of Sionna Therapeutics with a rating of Buy
Stifel initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $32.00
Guggenheim initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $45.00
10-Q - Sionna Therapeutics, Inc. (0002036042) (Filer)
8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
DEFA14A - Sionna Therapeutics, Inc. (0002036042) (Filer)
3 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)